DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
29 hedge funds and large institutions have $10.9M invested in DMK Pharmaceuticals Corporation Common Stock in 2015 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 6 closing their positions.
350% more call options, than puts
Call options by funds: $9K | Put options by funds: $2K
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
12% more capital invested
Capital invested by funds: $9.8M → $10.9M (+$1.13M)
0% more funds holding
Funds holding: 29 → 29 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Trading
New York
|
+$410K |
| 2 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
+$216K |
| 3 |
SCM
Sio Capital Management
New York
|
+$182K |
| 4 |
MSU
Mizuho Securities USA
New York
|
+$89.7K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$65.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$204K |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
-$59K |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$54.4K |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$53K |
| 5 |
EEG
E.E. Geduld
|
-$43.2K |
DMK Hedge Fund Activity: Q2 2015 in Review
29 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q2 2015, worth a combined $10.9M — up 12% from $9.8M a quarter earlier.
Fund positioning in DMK was balanced in Q2 2015: 6 funds opened new positions, 6 closed out, 8 added to existing stakes and 7 trimmed.
The largest buyer was Walleye Trading, opening a new position worth an estimated $410K. The largest seller was Raymond James & Associates, exiting entirely with an estimated $204K sold.
- 29 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q2 2015, unchanged from Q1 2015.
- Funds reported $10.9M of DMK Pharmaceuticals Corporation Common Stock stock for Q2 2015, up 12% quarter-over-quarter.
- 6 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q2 2015 and 6 closed out, a net change of 0 holders.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q2 2015 was Walleye Trading, an estimated $410K added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q2 2015 was Raymond James & Associates, an estimated $204K sold.
Based on aggregated 13F filings for Q2 2015.